Yuyi Chen

Dr. Yuyi Chen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2019 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
YCYuyi Chen
Yuyi Chen
YZYong-Hua Zhang
Yong-Hua Zhang
XCXin Chen
Xin Chen
WHWei-Ping Huang
Wei-Ping Huang
BXBei Xu
Bei Xu
YCYanhong Chen
Yanhong Chen

5 March 2021 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
YCYuyi Chen
Yuyi Chen
YZYonghua Zhang
Yonghua Zhang
LQLulu Qu
Lulu Qu
WHWeiping Huang
Weiping Huang
XSXi Su
Xi Su
YCYanhong Chen
Yanhong Chen

24 November 2023 in Medicine
Verified
Journal Article
Open access
YCYuyi Chen
Yuyi Chen
LLLin Liang
Lin Liang
PTPengchao Tian
Pengchao Tian
JFJiayu Feng
Jiayu Feng
LHLi-Yan Huang
Li-Yan Huang
Yuhui ZhangYuhui Zhang
Yuhui Zhang
The aim of this study was to investigate the clinical characteristics and prognosis of patients hospitalized with heart failure with preserved ejection fraction (HFpEF) and low N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Seven hundred ninety consecutive patients hospitalized with HFpEF from 2006 to 2017 were enrolled. Clinical characteristics and outcomes were compared between low NT-proBNP group (<300 ng/L) and elevated NT-proBNP group (≥300 ng/L). 108 HFpEF patients (13.7%) presented with low NT-proBNP levels. Age, body mass index, atrial fibrillation, New York Heart Association functional class, and albumin were independent predictors of low NT-proBNP levels in HFpEF patients. During the median follow-up duration of 1103 days, 11 patients (10.2%) in low NT-proBNP group suffered from primary endpoint event. Elevated NT-proBNP group had a higher risk of all-cause death or heart transplantation than low NT-proBNP group (adjusted HR [95%CI]: 2.36 [1.24,4.49], P = .009). Stratified analyses showed that the association between NT-proBNP (elevated NT-proBNP group vs low NT-proBNP group) and risk of all-cause death or heart transplantation was stronger in non-atrial fibrillation patients than in atrial fibrillation patients (P value for interaction = .025). Furthermore, the associations between NT-proBNP and risk of all-cause death or heart transplantation were stronger in younger and male patients than in older and female patients. However, both subgroups only reached borderline significant (P values for interaction = .062 and .084, respectively). Our findings suggest that low NT-proBNP levels were common in patients hospitalized with HFpEF. Patients with HFpEF and low NT-proBNP levels had a better prognosis than those with elevated NT-proBNP levels, particularly in younger, male, and non-atrial fibrillation patients.

26 March 2026 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
YCYuyi Chen
Yuyi Chen
ACAmanda Chang
Amanda Chang
FCFangyuan Cheng
Fangyuan Cheng
DVDavide Di Vece
Davide Di Vece
MWMichael Würdinger
Michael Würdinger
KLKan Liu
Kan Liu
Background: An effective risk stratification model on hospitalized patients with takotsubo syndrome (TTS) helps guide treatment to mitigate adverse events and improve prognosis. We aimed to develop a nomogram for predicting in‐hospital death in a multinational cohort of TTS patients. Methods: We enrolled 829 TTS patients from AmSC Research Network, InterTAK registry and ChiTTS registry, classified into the training ( n = 578), test ( n = 145) and external validation ( n = 106) cohorts. Results: Body mass index (BMI), chronic kidney disease (CKD), neurologic disorders, cardiogenic shock, low systolic blood pressure (SBP, <122 mmHg) and abnormal white blood cell (WBC, ≥11.3 × 10 9 /L) were independent positive predictors, while chest pain was an independent negative predictor of in‐hospital death. A nomogram was constructed to predict in‐hospital death in TTS patients based on these seven independent variables, which showed that the area under the curves (AUCs) in the training and test cohorts were .854 (95% CI: .805–.904, p < .001) and .836 (95% CI: .737–.934, p < .001), respectively. The calibration curves showed good consistency between the prediction of the nomogram and the actual observation in both the training and test cohorts. Decision curve analyses indicated that the use of the nomogram to predict in‐hospital death in TTS patients could provide better net benefit than the ‘treat all’ or ‘treat none’ strategies when the threshold probability ranged from 2% to 75% in the training cohort and from 2% to 72% in the test cohort. The nomogram was further validated, with AUC of .838 (95% CI: .663–1.000, p = .003) in the external validation cohort. Conclusions: The nomogram, composed of BMI, CKD, neurologic disorders, chest pain, cardiogenic shock, low SBP and abnormal WBC, helps predict in‐hospital death in TTS patients.